Change in revenue reporting

As announced in connection with the publication of the 2006 full-year results, Novozymes will change its revenue reporting in 2007.

As announced in connection with the publication of the 2006 full-year results, Novozymes will change its revenue reporting in 2007. With the increasing activities within solutions for the biopharmaceutical industry, it has been decided to report these activities as a separate business area, creating more revenue transparency.

The new business area is named Biopharmaceutical Ingredients, and will comprise the activities related to Novozymes Delta, Novozymes GroPep, Novozymes Biopharma and also the research project within recombinant human serum albumin (rHSA).

Historically these revenue streams have been reported as other technical enzymes. Table 1 below discloses a breakdown of 2005 and 2006 quarterly sales of other technical enzymes in the old reporting and the new reporting split between technical enzymes and biopharmaceutical ingredients.

Table 1. 

1Q05 2Q05 3Q05 4Q05 2005 1Q06 2Q06 3Q06 4Q06 2006
DKKm
Old reporting
Total technical enzymes 374 425 442 479 1,720 476 490 520 625 2,111
New reporting
Technical enzymes 359 400 428 458 1,645 453 469 505 550 1,977
Biopharmaceutical ingredients   15   25   14   21     75   23   21   15   75    134